Skip to main content

Cameron Fox, Ph.D.


Publications: Click here

I grew up in Montana and graduated from Montana State University- Billings. During undergrad I worked in Prof. David Butler's lab and my research focused on the pathogenesis of candida albicans, a common yeast pathogen that infects a large percentage of immunocompromised individuals and transplant patients. I focused on identifying targets of Grr1, a ubiquitin ligase shown to be essential in hyphea formation.
After graduating, I moved to Boston, MA, to work in Dr. Adam Bass's lab at the Dana Farber Cancer Institute where we first identified and characterized the genomic landscape of esophageal adenocarcinomas. We used next generation sequencing and SNP arrays to profile a large number of tumors and identified some key drug-able alterations within the tumor type. Using this data, Dr. Jihun Kim and I worked understand the poor patient outcomes from a clinical trial using the HER2 inhibitor Herceptin (ToGA trial). We discovered a number of common innate resistance mechanisms present in esophageal adenocarcinomas and hope this work will spawn trials to overcome the resistance.
My graduate work in the KUMC MD/PhD program occurred in Dr. Baumann's lab at the Stowers Institute. My project centered around the role of RNA modifications, particularly methylation marks such as m6A and 5mC, and their role in telomerase biology. I identified a novel RNA nuclear exosome targeting complex adaptor which preferentially binds modified RNA and leads to its degradation. This complex not only targets the telomerase RNA subunit but also other long noncoding RNAs and antisense transcripts.

Mentor: Peter Bauman, Ph.D.

Last modified: Jun 28, 2019


Cameron Fox, Ph.D.